-
公开(公告)号：US09745371B2
公开(公告)日：2017-08-29
申请号：US15138635
申请日：2016-04-26
Applicant: Janssen Biotech, Inc.
Inventor： Christopher Alderfer , Dariusz Janecki , Xuesong Liu , Melissa Murdock , Sheng-Jiun Wu , Marc Mercken , Marc Vandermeeren , Thomas Malia
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
-
公开(公告)号：US20160304593A1
公开(公告)日：2016-10-20
申请号：US15138635
申请日：2016-04-26
Applicant: Janssen Biotech, Inc.
Inventor： Christopher Alderfer , Dariusz Janecki , Xuesong Liu , Melissa Murdock , Sheng-Jiun Wu , Marc Mercken , Marc Vandermeeren , Thomas Malia
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to anti- PHF-tau antibodies and methods of making and using them.
Abstract translation: 本发明涉及抗-PHF-tau抗体及其制备和使用方法。
-
公开(公告)号：US09371376B2
公开(公告)日：2016-06-21
申请号：US14363888
申请日：2012-12-19
Applicant: Janssen Biotech, Inc.
Inventor： Christopher Alderfer , Dariusz Janecki , Xueson Liu , Melissa Murdock , Sheng-Jiun Wu , Marc Mercken , Marc Vandermeeren , Thomas Malia
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Anti-PHF-tau antibodies and methods of making and using them are disclosed.
Abstract translation: 公开了抗-PHF-tau抗体及其制备和使用方法。
-
公开(公告)号：US09102737B2
公开(公告)日：2015-08-11
申请号：US13835518
申请日：2013-03-15
Applicant: Janssen Biotech, Inc.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
-
-
Search Results
24
records
(took 0.019 seconds)
